ClinicalTrials.gg
CompletedNCT00645398Updated Jan 25, 2021

A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia

A Phase 3 interventional study of Pregabalin and Pregabalin in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 102 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
751
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.

Enrollment
2nd of 30
751 · median 199
Started
2004
the only one that year
Phase 3
13 of 30
none open now
Registered
7th of 30
by date
Lead sponsor
15 of 30
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 2nd largest by enrollment, is the only one that started in 2004, is one of 13 in phase 3, and was the 7th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pregabalin in Fibromyalgia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pregabalin versus placebo for the symptomatic relief of pain associated with fibromyalgia. If this objective is met, then the second objective will be to evaluate the efficacy and safety of pregabalin versus placebo for the management of fibromyalgia (pain, patient global assessment, and functional status). Additionally, the study will evaluate the efficacy of pregabalin versus placebo to improve sleep, fatigue, and mood disturbance associated with fibromyalgia.

03

Conditions studied

  • Fibromyalgia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who met the American College of Rheumatology (ACR) criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)
  • Patients who completed at least 4 pain diaries within the last 7 days and the average pain score must have been ≥4, and had a score of ≥40 mm on the Visual Analogue Scale (VAS) of the SF-MPQ at screening (Visit 1) and randomization (Visit 2)

Exclusion criteria

Exclusion Criteria:

  • Patients with other severe pain that may confound assessment or self-evaluation of the pain associated with fibromyalgia
  • Patients with any inflammatory muscle or rheumatologic disease other than fibromyalgia, active infections, or untreated endocrine disorders
  • Patients with severe depression
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
751 participants (actual)

Study arms

  • Experimental
    A

    Drug: Pregabalin

  • Experimental
    B

    Drug: Pregabalin

  • Experimental
    C

    Drug: Pregabalin

  • Placebo comparator
    D

    Drug: Placebo

Interventions

  • Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).

  • Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).

  • Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).

  • DrugPlacebo

    Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).

06

What researchers measure

Primary outcomes

  1. Endpoint mean pain score derived from the subject's daily pain diary

    Time frame: Endpoint

  2. Patient Global Assessment (Patient Global Impression of Change) at Termination Visit

    Time frame: Weeks 5 and 13

  3. Change from baseline in functioning (score created from the Short Form-36 [SF-36] Social and Physical Functioning, Fibromyalgia Impact Questionnaire [FIQ]-Total Score, and Sheehan Disability Scale [SDS] Total Score) at Termination Visit

    Time frame: Baseline and Weeks 5, 9, and 13

Secondary outcomes

  1. Change from baseline in FIQ scores at Weeks 5, 9, and 13

    Time frame: Baseline and Weeks 5, 9, and 13

  2. Change from baseline in SDS scores at Weeks 5, 9, and 13

    Time frame: Baseline and Weeks 5, 9, and 13

  3. Change from baseline in Medical Outcomes Study (MOS)-Sleep Scale scores at Weeks 5, 9, and 13

    Time frame: Baseline and Weeks 5, 9, and 13

  4. Quality of Sleep Score from the Daily Sleep Diary

    Time frame: Daily

  5. Change from baseline in Multidimensional Assessment of Fatigue (MAF) scores at Weeks 5, 9, and 13

    Time frame: Baseline and Weeks 5, 9, and 13

  6. Change from baseline in Hospital Anxiety and Depression Scale (HADS) scores at Week 13

    Time frame: Baseline and Week 13

  7. Change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) scores at Weeks 5, 9, and 13

    Time frame: Screening, baseline, and Weeks 5, 9, and 13

  8. Change from baseline in Fibromyalgia Health Assessment Questionnaire (F-HAQ) scores at Weeks 9 and 13

    Time frame: Baseline and Weeks 9 and 13

  9. Adverse events

    Time frame: Weeks 1, 2, 5, 9, 13, and at follow-up

  10. Physical examination, including vital signs and weight

    Time frame: Baseline and Week 5 (vital signs only) and 13

  11. Neurological examination

    Time frame: Screening and Week 13

  12. Electrocardiogram

    Time frame: Screening and Week 13

  13. Laboratory tests, including chemistry and hematology

    Time frame: Baseline and Weeks 5, 13, and at follow-up

  14. Urinalysis

    Time frame: Baseline and Weeks 13 and at follow-up

07

Study locations

102 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35294, United States
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Paradise Valley, Arizona 85253, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85023, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85032, United States
  • Pfizer Investigational Site
    Scottsdale, Arizona 85254, United States
  • Pfizer Investigational Site
    Hot Springs, Arkansas 71913, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    Beverly Hills, California 90211, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Los Alamitos, California 90720, United States
  • Pfizer Investigational Site
    Newport Beach, California 92660, United States
  • Pfizer Investigational Site
    Northridge, California 91324-4625, United States
  • Pfizer Investigational Site
    Northridge, California 91335, United States
  • Pfizer Investigational Site
    Pismo Beach, California 93449, United States
  • Pfizer Investigational Site
    Redondo Beach, California 90277, United States
  • Pfizer Investigational Site
    Riverside, California 92501, United States
  • Pfizer Investigational Site
    Riverside, California 92506, United States
  • Pfizer Investigational Site
    Walnut Creek, California 94598, United States
  • Pfizer Investigational Site
    Whittier, California 90601, United States
  • Pfizer Investigational Site
    Danbury, Connecticut 06810, United States
  • Pfizer Investigational Site
    New Milford, Connecticut 06776, United States
  • Pfizer Investigational Site
    Stratford, Connecticut 06615, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33761, United States
  • Pfizer Investigational Site
    Miami, Florida 33173, United States
  • Pfizer Investigational Site
    Ocala, Florida 34474, United States
  • Pfizer Investigational Site
    Palm Beach Gardens, Florida 33410, United States
  • Pfizer Investigational Site
    Plantation, Florida 33317, United States
  • Pfizer Investigational Site
    Plantation, Florida 33324, United States
  • Pfizer Investigational Site
    Saint Petersburg, Florida 33703, United States
  • Pfizer Investigational Site
    Saint Petersburg, Florida 33709, United States
  • Pfizer Investigational Site
    Saint Petersburg, Florida 33710, United States
  • Pfizer Investigational Site
    Sunrise, Florida 33351-6637, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33409, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30328, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30342, United States
  • Pfizer Investigational Site
    Decatur, Georgia 30033-5930, United States
  • Pfizer Investigational Site
    Boise, Idaho 83704, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60610, United States
  • Pfizer Investigational Site
    Maywood, Illinois 60153, United States
  • Pfizer Investigational Site
    Oak Brook, Illinois 60523, United States
  • Pfizer Investigational Site
    Peoria, Illinois 61614, United States
  • Pfizer Investigational Site
    Kansas City, Kansas 66160, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66210, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66215, United States
  • Pfizer Investigational Site
    Madisonville, Kentucky 42431, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70114, United States
  • Pfizer Investigational Site
    Newton, Massachusetts 02462, United States
  • Pfizer Investigational Site
    East Lansing, Michigan 48823, United States
  • Pfizer Investigational Site
    Kalamazoo, Michigan 49009, United States
  • Pfizer Investigational Site
    Lansing, Michigan 48917, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64114, United States
  • Pfizer Investigational Site
    Lebanon, New Hampshire 03766, United States
  • Pfizer Investigational Site
    Princeton, New Jersey 08540, United States
  • Pfizer Investigational Site
    Albany, New York 12205, United States
  • Pfizer Investigational Site
    New York, New York 10003, United States
  • Pfizer Investigational Site
    Rochester, New York 14618, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28210, United States
  • Pfizer Investigational Site
    Wilmington, North Carolina 28401, United States
  • Pfizer Investigational Site
    Wilmington, North Carolina 28403, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45219, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43124, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43212, United States
  • Pfizer Investigational Site
    Mogadore, Ohio 44260, United States
  • Pfizer Investigational Site
    Toledo, Ohio 43623, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73109, United States
  • Pfizer Investigational Site
    Eugene, Oregon 97401, United States
  • Pfizer Investigational Site
    Medford, Oregon 97504, United States
  • Pfizer Investigational Site
    Portland, Oregon 97201, United States
  • Pfizer Investigational Site
    Altoona, Pennsylvania 16601, United States
  • Pfizer Investigational Site
    Altoona, Pennsylvania 16602, United States
  • Pfizer Investigational Site
    Duncansville, Pennsylvania 16635, United States
  • Pfizer Investigational Site
    Johnstown, Pennsylvania 15904, United States
  • Pfizer Investigational Site
    Mechanicsburg, Pennsylvania 17055, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19115, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19146, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15218, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • Pfizer Investigational Site
    Pottstown, Pennsylvania 19610, United States
  • Pfizer Investigational Site
    West Reading, Pennsylvania 19611-1124, United States
  • Pfizer Investigational Site
    Wyomissing, Pennsylvania 19610, United States
  • Pfizer Investigational Site
    Anderson, South Carolina 29621, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29406, United States
  • Pfizer Investigational Site
    Greer, South Carolina 29651, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38104, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38119, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
  • Pfizer Investigational Site
    Lubbock, Texas 79424, United States
  • Pfizer Investigational Site
    Richardson, Texas 75080, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229-4540, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84102, United States
  • Pfizer Investigational Site
    Woodstock, Vermont 05091-0437, United States
  • Pfizer Investigational Site
    Woodstock, Vermont 05091, United States
  • Pfizer Investigational Site
    Virginia Beach, Virginia 23454, United States
  • Pfizer Investigational Site
    Seattle, Washington 98104, United States

Showing the first 100 of 102 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601-9. doi: 10.1185/03007995.2015.1134463. Epub 2016 Jan 27. PubMed 26694975 ↗
  • Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, McQuay HJ. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskelet Disord. 2011 Jun 3;12:125. doi: 10.1186/1471-2474-12-125. PubMed 21639874 ↗
  • Bhadra P, Petersel D. Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. Expert Opin Pharmacother. 2010 Dec;11(17):2805-12. doi: 10.1517/14656566.2010.525217. Epub 2010 Nov 2. PubMed 21039311 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2008
First posted
Mar 27, 2008
Start
Sep 2004
CompletionActual
Jun 2005
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00645398
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
Sep 2004
Completion
Jun 2005
Last update
Jan 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion